Published by IMARC Services Private Limited
Posted on September 14, 2021
4 min readLast updated: February 10, 2026
Add as preferred source on Google
According to IMARC Group’s latest report, titled“Natural Killer Cells Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, the global natural killer cells therapeutics market exhibited strong growth during 2015-2020. Natural killer (NK) cells therapeutics target various pathogenic antigens with efficient cytotoxicity to lower the risk of cytokine storms. They can be produced from a wide range of sources without the help of patient-specific immune cells. Some strategies that have been developed to improve the efficacy of NK cells therapeutics include ex vivo pre-conditioning with cytokines or small molecular drugs, with a focus on maximizing the therapeutic effects of allogeneic NK cells. This can also help in unleashing a strong and sustained anti-cancer immune-mediated attack.
Request for a PDF sample of this report: https://www.imarcgroup.com/natural-killer-cells-therapeutics-market/requestsample
The rising number of individuals with cancer, infectious diseases, liver disorders, etc., is primarily fueling the need for NK cells therapeutics. This is attributable to various factors, including unhealthy dietary patterns, sedentary lifestyles, growing air pollution, increasing tobacco products and alcohol consumption, etc. Additionally, several healthcare organizations are developing novel methods and technologies for boosting the immune response of cancer patients through allogeneic, off-the-shelf NK cell-based therapies. Furthermore, the governing agencies across numerous countries are funding financial schemes for cancer patients, which are expected to drive the market for NK cells therapeutics in the coming years. Looking forward, IMARC Group expects the market to grow at a CAGR of around 15% during 2021-2026.
Competitive Landscape with Key Players:
· Affimed GmbH
· Bristol-Myers Squibb Company
· Fate Therapeutics
· Fortress Biotech Inc.
· Glycostem Therapeutics
· Innate Pharma S.A.
· Kuur Therapeutics Inc
· Athenex Inc
· Nkarta Inc.
· Takeda Pharmaceutical Company Limited
· Ziopharm Oncology Inc.
Breakup by Therapeutics:
· NK Cell Therapies
· NK Cell Directed Antibodies
Breakup by Application:
· Cancer
· Gastrointestinal Diseases
· Immunoproliferative Disorders
· Others
Breakup by End User:
· Hospitals
· Research Centers and Institutes
· Others
Breakup by Region:
· North America (United States, Canada)
· Europe (Germany, France, United Kingdom, Italy, Spain, Others)
· Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
· Latin America (Brazil, Mexico, Others)
· Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Others)
Ask Analyst for Customization and Explore full report with TOC & List of Figures: https://www.imarcgroup.com/natural-killer-cells-therapeutics-market
We are updating our reports, If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.
Key highlights of the report:
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
Related Reports by IMARC Group:
Acute Myeloid Leukemia Therapeutics Market: https://www.imarcgroup.com/acute-myeloid-leukemia-therapeutics-market
Indonesia Prepaid Cards Market: https://www.imarcgroup.com/indonesia-prepaid-cards-market
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, and nanotechnology industries. We also provide cost model and manufacturing setup project reports through Syndicated Analytics, a subsidiary of IMARC Group.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact US:
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas: – +1 631 791 1145 | Africa and Europe: – +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
The rising number of individuals with cancer, infectious diseases, and liver disorders is primarily fueling the need for NK cells therapeutics.
Key players include Affimed GmbH, Bristol-Myers Squibb Company, Fate Therapeutics, and Takeda Pharmaceutical Company Limited, among others.
NK cell therapies are primarily applied in treating cancer, gastrointestinal diseases, and immunoproliferative disorders.
The report highlights regions including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
End users of NK cell therapies include hospitals, research centers, and institutes.
Explore more articles in the Research Reports category
